MARCO RENAZCO: Open Payments
NPI 1518038751 · KATY, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,521 in 75 payments from 19 companies in 2025. Trend: 2023 $1,410 · 2024 $1,114 · 2025 $1,521
Food & beverage: $1,521
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 16 | $265 |
| Otsuka America Pharmaceutical, Inc. | 8 | $173 |
| E.R. Squibb & Sons, L.L.C. | 4 | $108 |
| Vanda Pharmaceuticals Inc. | 6 | $104 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $98 |
| Vertical Pharmaceuticals, LLC | 5 | $97 |
| Tris Pharma Inc | 4 | $86 |
| Axsome Therapeutics, Inc. | 3 | $76 |
| Corium, LLC | 5 | $74 |
| Bausch Health US, LLC | 3 | $63 |
Products named: VRAYLAR, REXULTI, COBENFY, FANAPT, CAPLYTA, Relexxii, Dyanavel XR, Auvelity.
Industry payments across TX — which companies pay providers there.
